ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Medexus Pharmaceuticals Inc (QX)

Medexus Pharmaceuticals Inc (QX) (MEDXF)

2,88
0,03
(1,05%)
Fermé 22 Juin 10:00PM

Medexus Pharmaceuticals Inc (QX) (MEDXF) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,88
( 1,05% )
Prix Achat
2,48
Prix Vente
3,19
Volume échangé
1 000
2,87 Fourchette du Jour 2,89
1,80 Plage de 52 semaines 3,042
Cap du marché
Clôture Veille
2,85
Ouverture
2,87
Dernière Transaction
400
@
2.88
Dernière heure de transaction
Volume financier
US$ 2 878
VWAP
2,8776
Volume moyen (3 m)
US$ 50 707
Actions en circulation
31 834 683
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-333,41
Bénéfice par action (BPA)
-0,01
Chiffre d'affairess (LTM)
99,43M
Bénéfice net (LTM)
-272k

À propos de Medexus Pharmaceuticals Inc (QX)

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant... Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Toronto, Canada
Fondé
2026
Medexus Pharmaceuticals Inc (QX) est coté dans le secteur Healthcare de la OTC Markets avec le ticker MEDXF. Le dernier cours de clôture d'Medexus Pharmaceuticals (QX) était de US$2,85. Au cours de la dernière année, les actions de Medexus Pharmaceuticals (QX) ont été négociées dans une fourchette de prix de US$ 1,80 à US$ 3,042.

Medexus Pharmaceuticals (QX) compte actuellement 31 834 683 actions en circulation. La capitalisation boursière d'Medexus Pharmaceuticals (QX) est de US$91,68 million. Medexus Pharmaceuticals (QX) a un ratio cours/bénéfice (ratio PE) de -333.41.

MEDXF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.020.6993006993012.8632.7875102472.88547021CS
4-0.021998-0.7580294679732.90199832.51101962.85345221CS
120.6730.31674208142.213.0422.1365108342.80517283CS
260.96550.39164490861.9153.0421.8325128952.38154869CS
520.626.31578947372.283.0421.8125222.21112917CS
1561.9472208.7478559180.93283.880.9328148811.98773649CS
260-3.215-52.74815422486.0956.790.585151852.10128133CS

MEDXF - Frequently Asked Questions (FAQ)

What is the current Medexus Pharmaceuticals Inc (QX) share price?
The current share price of Medexus Pharmaceuticals Inc (QX) is US$ 2,88
How many Medexus Pharmaceuticals Inc (QX) shares are in issue?
Medexus Pharmaceuticals Inc (QX) has 31 834 683 shares in issue
What is the market cap of Medexus Pharmaceuticals Inc (QX)?
The market capitalisation of Medexus Pharmaceuticals Inc (QX) is USD 91,68M
What is the 1 year trading range for Medexus Pharmaceuticals Inc (QX) share price?
Medexus Pharmaceuticals Inc (QX) has traded in the range of US$ 1,80 to US$ 3,042 during the past year
What is the PE ratio of Medexus Pharmaceuticals Inc (QX)?
The price to earnings ratio of Medexus Pharmaceuticals Inc (QX) is -333,41
What is the cash to sales ratio of Medexus Pharmaceuticals Inc (QX)?
The cash to sales ratio of Medexus Pharmaceuticals Inc (QX) is 0,92
What is the registered address of Medexus Pharmaceuticals Inc (QX)?
The registered address for Medexus Pharmaceuticals Inc (QX) is 10 King Street East, Toronto, Ontario, M5C 1C3
What is the Medexus Pharmaceuticals Inc (QX) website address?
The website address for Medexus Pharmaceuticals Inc (QX) is www.medexus.com
Which industry sector does Medexus Pharmaceuticals Inc (QX) operate in?
Medexus Pharmaceuticals Inc (QX) operates in the Pharmaceuticals sector

MEDXF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock